Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 701 - 725 of 800 in total
XP12B is being developed by Xanodyne Pharmaceuticals for the treatment of menorrhagia (heavy menstrual bleeding). It was granted Fast Track status for this indication by the FDA in November 2004.
Investigational
Experimental
XR5944 is a DNA bis-intercalating anticancer drug. It has both intercalating and antineoplastic activities.
Investigational
Experimental
Experimental
Coagulation factor XIa is under investigation in clinical trial NCT01701947 (HEMOLEVEN® Expanded Access Program Prevention of Surgical/Postpartum Hemorrhage Severe Inherited Factor XI Deficiency).
Investigational
Xaluritamig is a novel humanized bispecific T cell recruiting antibody cross-reactive to human and nonhuman primate STEAP1 and CD3.
Investigational
Tamibarotene is a novel synthetic retinoid for acute promyelocytic leukaemia (APL). Tamibarotene is currently approved in Japan for treatment of recurrent APL, and is undergoing clinical trials in the United States.
Investigational
Arbaclofen, or STX209, is the R-enantiomer of baclofen. It is believed to be a selective gamma-amino butyric acid type B receptor agonist, and has been investigated as a treatment for autism spectrum disorder and fragile X syndrome in randomized, double blind, placebo controlled trials. It has also been investigated as...
Investigational
Matched Description: … receptor agonist, and has been investigated as a treatment for autism spectrum disorder and fragile X
Investigational
Xanthohumol is under investigation in clinical trial NCT01367431 (Xanthohumol and Metabolic Syndrome).
Investigational
Experimental
Investigational
Arbaclofen Placerbil is a prodrug of Arbaclofen, which is a selective gamma-amino-butyric acid type B receptor agonist and the R-enantiomer of baclofen. It was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties....
Investigational
Experimental
Experimental
XEN-D0501 is a tetrahydronaphthyl urea-based selective TRPV1 antagonist being investigated for the treatment of erythromelalgia.
Investigational
OTL-102 consists of autologous CD34+ enriched cells that contain hematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding the human gp91phox gene. It is being investigated for the treatment of X-linked chronic granulomatous disease.
Investigational
Matched Description: … It is being investigated for the treatment of X-linked chronic granulomatous disease. …
Fenobam is under investigation in clinical trial NCT00637221 (Open Label Study Investigating Safety and Efficacy of Fenobam anhydrous 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance Tasks, Adults With Fragile X Syndrome).
Investigational
Matched Description: … anhydrous 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance Tasks, Adults With Fragile X
Horse chestnut is a flowering plant commonly referred to as Aesculus hippocastanum. Unprocessed horse chestnut seeds contain a toxin called esculin (also spelled aesculin) that increases the risk of bleeding due to anticoagulant actions. These seeds are processed to remove the toxic component, resulting in purified horse chestnut seed extract...
Experimental
Matched Description: … Horse chestnut is a flowering plant commonly referred to as *Aesculus hippocastanum*. …
Curcuma xanthorrhiza oil is extracted from Curcuma xanthorrhiza Roxb., a member of the ginger family (Zingiberaceae) that is widely distributed in the region of Southeastern Asia . Curcuma xanthorrhiza is also known as Javanese Turmeric or Temoe Lawak . For centuries, Curcuma xanthorrhiza oil has been used as a traditional...
Nutraceutical
Experimental
Investigational
Matched Mixtures name: … Telom-X-gene …
Displaying drugs 701 - 725 of 800 in total